Nanobiotechnology and Nanomedicine Companies
(Links listed alphabetically)
A | B | C | D | E | F | G | H | I | J | K | L | M | N | O | P | Q | R | S | T | U | V | W | X | Y | Z | All
Showing results 1 - 25 of 252
The firm commercializes a family of self-assembling nanoscale scaffolds called PuraMatrix. 3DM's materials assemble upon injection into nanofibers, serving as a scaffold for tissue regeneration.
Develops Nanobodies, antibody-derived therapeutic proteins that contain the unique structural and functional properties of naturally-occurring heavy-chain antibodies.
The company's nab™ drug delivery technology uses albumin nanoparticles to deliver drugs into tumors.
Accium offers laboratory services based on its Accelerator Mass Spectrometry platform used to detect 14C/12C ratios which provided 1,000 times more sensitivity than the most sensitive method available today such as LC/MS. It is now possible to trace biomolecule delivery in healthy subjects with low attomole sensitivity.
Develops in-vitro models of cell and tissue systems. They simulate the transport of substances and formulations across biological barriers, from which conclusions regarding permeability and absorption can be drawn.
The company has developed a proprietary formulation technology called HDDS that converts drugs that do not dissolve well in water, or hydrophobic drugs, into microparticles or nanoparticles of the drug embedded in small microspheres, such that the drug can more rapidly dissolve in water.
The company has developed and produced superparamagnetic nanoparticles for in vitro diagnostic and life sciences.
Advancell is active in nanomedicine. The company has two divisions: Pharma, which focuses its activity on the development of innovative drugs through the search for new applications for already-known molecules, and Services and Reagents, which uses cell-based in vitro methods to predict the efficacy, safety and mechanism of action of developing molecules.
Develops and to markets a novel, automated chip-based technology for mass spectrometry users with the microfluidics chip containing an array of nanoelectrospray nozzles.
Affymetrix GeneChip microarray technology is the industry-standard tool for analyzing complex genetic information. The GeneChip solution consists of oligonucleotide arrays, instruments to process and analyze the arrays, and software tools to manage and mine the data.
Akonni Biosystems is a molecular diagnostics (MDx) company that develops, manufactures, and markets integrated molecular diagnostic systems.
A nano-biotechnology company with a nanoscale drug discovery technique for systematically scanning 'molecular diversity space'. The company has also developed technology for molecular manufacturing.
Altogen Biosystems develops polymer-, lipid-, and dendrimer-based transfection technology by applying expertise in molecular biology, combinatorial chemistry, and cell biology.
The Ambion brand encompasses a complete range of products for researchers whose work involves RNA. These include products for the isolation, detection, quantification, amplification, and characterization of RNA.
AMRI is a chemistry-based drug discovery, development and manufacturing company, focusing on small molecule prescription drugs.
AnaSpec, Inc. is a leading provider of integrated proteomics solutions for worldwide life science research. With a vision for innovation through synergy, AnaSpec offers expertise in three primary technologies: peptides, detection reagents, and combinatorial chemistry. AnaSpec carries a broad product line of biochemicals and reagents for basic research, high-throughput screening and drug discovery. In conjunction, AnaSpec provides premier custom services including peptide synthesis, antibody production, and assay development.
ANP's mission is to develop cutting-edge technology platforms at the nano/bio interface and apply them in market sectors such as diagnostics/biodetection, protein/drug discovery, therapeutics, chem/bio defense, and homeland security.
Anteo Diagnostics specialises in the development and commercialisation of proprietary surface coatings for applications in the diagnostics and biotech industries. With Mix&Go we have developed ?molecular glues? which are used by our partners and customers to immobilize delicate biological molecules such as antibodies to synthetic surfaces.
AnyGen develops bio-new drugs and essential materials, especially new drug candidates based on physiologically active peptides, biologically functional materials, and chemical nanomaterials.
The company develops biomedical nanoparticle technology and products for research and treatment of human disease. They are developing NanoElectroPlex™, a proprietary tissue selective nanoparticle platform technology based on biodegradable macromolecular carriers.
The company has developed enabling nanotechnologies for the production of protein nanoparticles, polymer nanospheres and phospholipid nanosomes for the enhanced delivery of drugs.
ApoLife has developed platform yeast expression technologies for accelerated development of therapeutic antibodies (glycosylated and aglycosylated), antibody fragments, fusion proteins and next generation antibodies and subunit vaccines through its proprietary Twin Cassette yeast system.
Aposense is a clinical stage molecular imaging and drug development company, focused on the introduction of novel agents based on the identification and targeting of cells undergoing apoptosis (programmed cell death).
Develops and manufactures micelle-like nanoparticulate encapsulation technology for applications in food, cosmetics, pharmaceuticals and biotechnology.
Develops a nanostructured material that stops bleeding almost instantly.